Efficacy of garenoxacin in patients with macrolide-resistant Mycoplasma pneumoniae pneumonia Authors: Naoyuki Miyashita, Makoto Ogata, Naoki Fukuda, Akihisa Yamura, Tomoki Ito Published: 2026 ABSTRACT ABSTRACTThe prevalence of macrolide-resistant Mycoplasma pneumoniae in Japan is increasing once again. The therapeutic efficacy of quinolone garenoxacin was compared with minocycline, which is recommended as the first-choice drug in patients with macrolide-resistant M. pneumoniae pneumonia. Defervescence within 48 h after initiation of antibiotics was observed in 90.6% of garenoxacin and 90% of minocycline recipients. Our results indicated that garenoxacin can be considered as the first-choice drug for the treatment of macrolide-resistant M. pneumoniae pneumonia. INTRODUCTION Garenoxacin (Toyama Chemical Co., Ltd.) is a novel des-F(6)-quinolone antibacterial drug that lacks a fluorine substituent at the C-6 position in the quinolone ring, which had been believed to be indispensable in past fluoroquinolone antibacterial drugs (1). Garenoxacin has demonstrated highly potent activity against major respiratory pathogens (2–5), and clinical studies have confirmed its efficacy against atypical and bacterial pneumonia (6, 7). Furthermore, among quinolones, garenoxacin is less susceptible to drug resistance (8–12). For this reason, the Japanese Respiratory Society (JRS) pneumonia management guidelines, revised in 2024, recommended garenoxacin as the first-line drug for the empirical treatment of community-acquired pneumonia (CAP) (13). Macrolide-resistantMycoplasma pneumoniae emerged in Japan in 2000 and has since spread rapidly, primarily in East Asia (14–16). In 2012, the proportion of macrolide-resistant M. pneumoniae reached 80–90%. Since then, resistant strains have decreased year by year to 20–30% (17). However, since 2019, macrolide-resistant M. pneumoniae has begun to increase again, reaching 60% in 2024, raising concerns about further spread (17). While the efficacy of garenoxacin has been confirmed for macrolide-sensitive M. pneumoniae (6), no studies have examined the efficacy of garenoxacin for macrolide-resistant M. pneumoniae. In this study, we compared the efficacy of garenoxacin with minocycline for macrolide-resistant and -sensitive M. pneumoniae pneumonia to verify the validity of the revised JRS pneumonia guidelines. Minocycline was selected as the comparator drug because it is recommended as the first-line drug for M. pneumoniae pneumonia in the JRS pneumonia guidelines (13). This study was a non-randomized, physician-led antibiotic selection trial conducted at 12 facilities affiliated with Kansai Medical University Hospital between January 2024 and December 2025. Patients were selected from those with community-acquired pneumonia who presented to the hospital for the first time before antibiotic administration. A rapid Mycoplasma antigen test was performed on patients with a Mycoplasma Pneumonia Diagnostic Prediction Score of 5 or higher (specificity 99%), as recommended in the JRS pneumonia guidelines. Patients with positive antigen results were registered, and antibiotics were initiated before the resistance genes were identified. Cultivation and polymerase chain reaction (PCR) testing for M. pneumoniae were carried out as previously reported (16–18). All antigen-positive cases were also PCR-positive. A direct sequencing method was used to search for mutations at sites 2063, 2064, and 2617 in the M. pneumoniae 23S rRNA domain V gene region in isolates or samples with a positive PCR result, as previously reported (16–18). The severity of pneumonia was evaluated using the A-DROP system of predictive rules proposed by the JRS pneumonia guidelines (13). Frequencies were compared using Fisher’s exact test. Between-group comparisons of normally distributed data were performed using a Student’s t-test. Skewed data were compared using the Mann-WhitneyU test. The therapeutic efficacy of garenoxacin and minocycline against macrolide-sensitive and -resistant M. pneumoniae pneumonia was evaluated. The attending physicians made the antibiotic selection. Garenoxacin was administered at a dosage of 400 mg once daily and minocycline at 200 mg twice daily in accordance with the package insert accompanying each drug. If clinical symptoms and signs had not improved by the second visit, the attending physicians changed the antibiotic treatment to minocycline or other quinolones (examples include lasufloxacin, levofloxacin, tosufloxacin, moxifloxacin, and sitafloxacin). We assessed the clinical outcome using fever, as previous studies have also only used the number of days with a fever to evaluate the clinical outcome in macrolide-resistant patients (16–20). Additionally, we evaluated the therapeutic efficacy of antibiotic treatment after 48 h, as previous reports have shown that the mean number of days with a fever in macrolide-sensitive patients during macrolide administration is between 1 and 2 days (19, 20). The number of days with fever was defined as the day antibiotics were started, and fever reduction was defined as an initial body temperature of less than 37.0°C persisting for 24 h. During the study period, 71 cases of M. pneumoniae pneumonia were enrolled, of which 45 were macrolide-resistant. All of these patients had an A-to-G transition at position 2063 in domain V of the 23S rRNA gene (A2063G). Table 1 shows the patient background and clinical findings in the garenoxacin- and minocycline-treated groups. All patients had a fever of 38°C or higher at the start of treatment. There were no significant differences in clinical features between the two groups. TABLE 1Underlying conditions and clinical findings in patients with Mycoplasma pneumoniae pneumonia at the first examination between the garenoxacin and minocycline groupsbVariablesGarenoxacin groupMinocycline groupP valueNo. of patients5120Median age (IQR), years21.5 (17–30)20.8 (16–29)0.6776No. of males/females24/279/11>0.9999No. (%) of patients with co-morbid illnesses4 (7.8)2 (10.0)>0.9999No. (%) of patients with each pneumonia severity scorea Mild40 (78.4)16 (80.0)>0.9999 Moderate11 (21.6)4 (20.0)>0.9999No. (%) of patients with macrolide-resistant Mycoplasma pneumoniae pneumonia32 (62.7)10 (50.0)0.4224No. (%) of patients with the following clinical signs and symptoms Fever (≥38.0°C)51 (100)20 (100)>0.9999 Cough50 (98.0)19 (95.0)0.4869 Sputum production31 (60.8)13 (65.0)0.7922 Sore throat20 (39.2)9 (45.0)0.7894 Headache16 (31.4)5 (25.0)0.7742 Shortness of breath4 (7.8)2 (10.0)>0.9999Laboratory findings, median (IQR) White blood cells, mean (/µL)6,400 (5,300–8,700)6,600 (5,500–8,800)0.6288 C-reactive protein, mean (mg/dL)4.6 (1.8–9.5)3.5 (1.1–8.5)0.5984 Aspartate aminotransferase, U/L26 (20–37)27 (21–38)0.7351 Alanine aminotransferase, U/L24 (19–36)25 (18–37)0.7426 a Patients were stratified into four severity classes by the A-DROP system: 0 point = mildand 1 or 2 points. b Continuous values are presented as medians and interquartile ranges and categorical/binary values as counts and percentages. Underlying conditions and clinical findings in patients with Mycoplasma pneumoniae pneumonia at the first examination between the garenoxacin and minocycline groupsb Patients were stratified into four severity classes by the A-DROP system: 0 point = mildand 1 or 2 points. Continuous values are presented as medians and interquartile ranges and categorical/binary values as counts and percentages. Table 2 shows the treatment outcomes between the two groups. For patients with macrolide-sensitive M. pneumoniae pneumonia, fever subsided within 48 h in 94.7% of patients in the garenoxacin group and 90% of patients in the minocycline group. For patients with macrolide-resistant M. pneumoniae pneumonia, fever subsided within 48 h in 90.6% of patients in the garenoxacin group and 90% of patients in the minocycline group. In both groups, there were no cases requiring a change in antibiotic or the use of additional antibiotics, and all patients were cured. TABLE 2Clinical efficacies of garenoxacin and oral minocycline against mild to moderate macrolide-sensitive and macrolide-resistant M. pneumoniae pneumoniaMacrolide-sensitive patients:Macrolide-resistant patients:VariableGarenoxacinMinocyclineGarenoxacinMinocyclineNo. of patients19103210Mean age, years22.121.821.320.5No. of males/females9/104/615/175/5No. (%) of patients with defervescence within 48 h after antibiotic administration18 (94.7)9 (90.0)29 (90.6)9 (90.0)No. (%) of patients with antibiotic change at second visit0000 Clinical efficacies of garenoxacin and oral minocycline against mild to moderate macrolide-sensitive and macrolide-resistant M. pneumoniae pneumonia The JRS pneumonia guidelines revised in 2024 recommend garenoxacin, which is less likely to induce resistance, as the first-line drug for empirical treatment of CAP (13). Garenoxacin is effective against major bacterial pathogens that exhibit drug resistance (13, 21), but its efficacy against drug-resistant M. pneumoniae strains had not been evaluated. Our current study confirmed that the efficacy of garenoxacin against macrolide-resistant M. pneumoniae pneumonia is equivalent to that of minocycline, which is the first-line drug for macrolide-resistant M. pneumoniae pneumonia (13, 21). To date, no M. pneumoniae strains resistant to fluoroquinolones have been reported anywhere in the world. The limitations of this study include a non-randomized trial design, physician-driven antibiotic selection, and the use of fever resolution as the only clinical outcome without considering microbiological or radiological endpoints. Furthermore, there was an imbalance between the number of patients treated with garenoxacin and minocycline, and this discrepancy may affect the statistical significance of the results. Further investigation is needed. In conclusion, our results demonstrated that garenoxacin may be effective as a treatment for macrolide-resistantM. pneumoniae pneumonia. If minocycline cannot be used, garenoxacin should be considered.